860002-83-1Relevant academic research and scientific papers
Casein kinase 1[epsilon] inhibitor, pharmaceutical composition and application thereof
-
Paragraph 0207; 0211-0215, (2021/01/11)
The invention discloses a novel substituted pyrazolopyrimidine compound for inhibiting the activity of casein kinase 1[epsilon] (CK1[epsilon]), a stereoisomer or a stereoisomer mixture of the novel substituted pyrazolopyrimidine compound, a pharmaceutically acceptable salt or solvate of the novel substituted pyrazolopyrimidine compound, and application of the compound to preparation of medicine for treating diseases, disorders or symptoms benefiting from the inhibition of the activity of casein kinase 1[epsilon] (CK1[epsilon]). The compound has inhibitory activity on CK1[epsilon] kinase, OCI-LY10 cells and Karpas299 cells, shows good anti-tumor activity in an OCI-LY10 subcutaneous xenogeneic model, shows excellent synergistic anti-tumor activity when being combined with a BTK inhibitor, has good pharmacokinetic properties, and can be applied to treatment of diseases, disorders or symptoms, including cancers, autoimmune diseases and the like, which benefit from inhibition of casein kinase 1[epsilon] activity, alone or in combination with other drugs.
Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4- one derivatives as CXCR3 chemokine receptor antagonists
Storelli, Stefania,Verdijk, Pauline,Verzijl, Dennis,Timmerman, Henk,Van De Stolpe, Andrea C.,Tensen, Cornelis P.,Smit, Martine J.,De Esch, Iwan J. P.,Leurs, Rob
, p. 2910 - 2913 (2007/10/03)
A series of 3-phenyl-3H-quinazolin-4-ones have been synthesized and tested for affinity and activity at the chemokine CXCR3 receptor. The most potent compound (1d) has been evaluated using radioligand binding and calcium mobilization assays and is considered a useful tool for further characterization of the CXCR3 receptor.
